AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HAE

Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers

Haemonetics shares rose 12% after CSL updated its plans to transition all U.S. plasma centers to Haemonetics' NexSys devices by 2027. The deal, initially disclosed in August, was expanded from a partial to a full rollout. Haemonetics' fiscal 2026 revenue was $1.33B, with organic growth at 1.1%. The stock trades at 21x forward earnings, above its 5-year average of 19.1x.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The news provides a fresh, material contract update that directly drove a 12% share surge, offering a clear trading trigger.

02

Market read

The contract expansion is a primary catalyst for Haemonetics' stock rally and may influence the broader medical device sector.

03

What to watch

Potential supply chain constraints for NexSys devices could delay full rollout.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Haemonetics disclosed an updated supply agreement with CSL Plasma, expanding the rollout to all U.S. centers by 2027, removing prior uncertainty.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics shares jumped 12% after CSL updated its rollout to move all U.S. plasma centers to NexSys by end‑2027.

Expected impact

likely upward pressure as market prices in the larger, timed CSL deal.

Evidence & confidence

The deal removes uncertainty and expands a major customer, supporting a sustained price rally.

$CSLLYBullishMedium confidence
Context

CSL (CSLLY) announced it will move all its U.S. plasma centers onto Haemonetics' NexSys devices by end‑2027.

Expected impact

neutral to modestly positive as the contract is already reflected in CSL's own valuation.

Evidence & confidence

The announcement confirms a major procurement but does not directly alter CSL's revenue guidance.

Market effects

Sector

Strengthens the medical device and plasma collection sector by confirming a large, long‑term contract.

Regional

U.S. healthcare equipment market sees a boost from the expanded CSL partnership.

Global

Highlights growing demand for advanced plasma collection technology worldwide.

Counterpoint

What could challenge this read

If CSL later reduces volumes or faces regulatory hurdles, the upside may be limited.

Key entities

  • Company
    Haemonetics

    Medical device maker supplying NexSys plasma collection systems.

  • Company
    CSL Plasma

    Operator of U.S. plasma collection centers, now committing to full NexSys rollout.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com